LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 147

Search options

  1. Article ; Online: Exploring cell-free assays for COVID-19 serosurvey.

    Inchauste, Lucia / Nurtop, Elif / Brisbarre, Nadège / Ninove, Laetitia / Gallian, Pierre / de Lamballerie, Xavier / Priet, Stéphane

    Scientific reports

    2024  Volume 14, Issue 1, Page(s) 6096

    Abstract: Serosurveys to monitor immunity toward COVID-19 in the population are primarily performed using an ELISA to screen samples for SARS-CoV-2 antibodies, followed by confirmation by a virus neutralization test, which is considered the Gold Standard. However, ...

    Abstract Serosurveys to monitor immunity toward COVID-19 in the population are primarily performed using an ELISA to screen samples for SARS-CoV-2 antibodies, followed by confirmation by a virus neutralization test, which is considered the Gold Standard. However, virus neutralization test may not be feasible for some laboratories because of the requirement for specific facilities and trained personnel. In an attempt to address this limitation, we evaluated three cell-free methods as potential alternatives for assessing SARS-CoV-2 seroprevalence in human population from plasma. We report the establishment of two inhibition ELISAs designed to detect anti-Spike RBD IgG antibodies and a microsphere quantitative suspension array technology assay, based on the Luminex xMAP platform, to measure the presence of antibodies against various SARS-CoV-2 antigens, including anti-RBD. These methods were also compared to a commercial chemiluminescent immunoassay designed for anti-RBD antibodies detection and to the combined ELISA + virus neutralization test strategy. These cell-free assays performed equally to estimate the percentage of positive and negative samples and could be used to determine the prevalence of SARS-CoV-2 antibodies in human population, at least in cohort with high-expected prevalence, without the use of seroneutralization assay.
    MeSH term(s) Humans ; COVID-19/diagnosis ; COVID-19/epidemiology ; SARS-CoV-2 ; Seroepidemiologic Studies ; Antibodies, Viral ; Antigens, Viral ; Antibodies, Neutralizing
    Chemical Substances Antibodies, Viral ; Antigens, Viral ; Antibodies, Neutralizing
    Language English
    Publishing date 2024-03-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-024-55852-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Seroprevalence surveys in blood donors population and complexity of immunization patterns.

    Gallian, Pierre / Brisbarre, Nadége / Isnard, Christine / Morel, Pascal / de Lamballerie, Xavier

    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine

    2022  Volume 30, Issue 1, Page(s) 21

    MeSH term(s) Humans ; Blood Donors ; Seroepidemiologic Studies ; Immunization ; Vaccination ; Surveys and Questionnaires ; Antibodies, Viral
    Chemical Substances Antibodies, Viral
    Language English
    Publishing date 2022-09-05
    Publishing country France
    Document type Letter
    ZDB-ID 1204698-x
    ISSN 1953-8022 ; 1246-7820
    ISSN (online) 1953-8022
    ISSN 1246-7820
    DOI 10.1016/j.tracli.2022.09.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Impact of vaccination on SARS-CoV-2 seroprevalence rate in French blood donors: An assessment as of July 2021.

    Gallian, Pierre / Slimani, Ahmed / Malard, Lucile / Morel, Pascal / de Lamballerie, Xavier

    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine

    2022  Volume 30, Issue 1, Page(s) 25–26

    MeSH term(s) Humans ; Blood Donors ; COVID-19/epidemiology ; COVID-19/prevention & control ; SARS-CoV-2 ; Seroepidemiologic Studies ; Vaccination ; Antibodies, Viral
    Chemical Substances Antibodies, Viral
    Language English
    Publishing date 2022-08-05
    Publishing country France
    Document type Letter
    ZDB-ID 1204698-x
    ISSN 1953-8022 ; 1246-7820
    ISSN (online) 1953-8022
    ISSN 1246-7820
    DOI 10.1016/j.tracli.2022.08.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Low neutralization capacity against SARS-CoV-2 Omicron BQ.1.1 of convalescent plasma collected during circulation of Omicron BA.1.

    Gallian, Pierre / Brisbarre, Nadége / Nurtop, Elif / Le Cam, Sophie / Franck, Touret / Isnard, Christine / Malard, Lucile / Laperche, Syria / Richard, Pascale / Morel, Pascal / Tiberghien, Pierre / de Lamballerie, Xavier

    Vox sanguinis

    2023  Volume 118, Issue 5, Page(s) 407–408

    MeSH term(s) Humans ; SARS-CoV-2 ; COVID-19/therapy ; COVID-19 Serotherapy ; Plasma ; Antibodies, Viral ; Antibodies, Neutralizing ; Neutralization Tests
    Chemical Substances Antibodies, Viral ; Antibodies, Neutralizing
    Language English
    Publishing date 2023-03-10
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 80313-3
    ISSN 1423-0410 ; 0042-9007
    ISSN (online) 1423-0410
    ISSN 0042-9007
    DOI 10.1111/vox.13418
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Preventing transfusion-transmitted malaria in France.

    Le Cam, Sophie / Houze, Sandrine / Barlet, Valerie / Maugard, Claude / Narboux, Céline / Morel, Pascal / Garraud, Olivier / Tiberghien, Pierre / Gallian, Pierre

    Vox sanguinis

    2021  Volume 116, Issue 9, Page(s) 943–945

    MeSH term(s) Blood Transfusion ; France/epidemiology ; Humans ; Malaria/epidemiology ; Malaria/prevention & control
    Language English
    Publishing date 2021-03-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 80313-3
    ISSN 1423-0410 ; 0042-9007
    ISSN (online) 1423-0410
    ISSN 0042-9007
    DOI 10.1111/vox.13097
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: SARS-CoV-2 and post-donation information: a one-year experience of the French haemovigilance network.

    Cappy, Pierre / Legrain-Jbilou, Saadia / Chabli, Lila / N'Debi, Melissa / Gallian, Pierre / Brisbarre, Nadège / Pillonel, Josiane / Morel, Pascal / Laperche, Syria

    Blood transfusion = Trasfusione del sangue

    2022  Volume 20, Issue 5, Page(s) 362–373

    Abstract: Background: There is growing evidence to support the hypothesis that SARS-CoV-2 is probably not transmissible by blood transfusion. In this study, we use the data gathered over one year by the French haemovigilance network on post-donation information ... ...

    Abstract Background: There is growing evidence to support the hypothesis that SARS-CoV-2 is probably not transmissible by blood transfusion. In this study, we use the data gathered over one year by the French haemovigilance network on post-donation information related to SARS-CoV-2, and virological investigations on corresponding plasma to explore viral transmission by transfusion.
    Materials and methods: Whenever a donor reported COVID-19 symptoms and/or a positive SARS-CoV-2 nasopharyngeal (NP) PCR test, information regarding diagnosis and symptoms was collected using a specific questionnaire, and repository plasmas were screened using the SARS-COV-2 R-GENE
    Results: We investigated 1,092 SARS-CoV-2-related post-donation information (PDI) reports. PDI donors were younger than the global donor population and donated more often in the Paris region. Sixty-eight percent reported a positive NP real-time (RT)-PCR or antigenic testing and 22% of these also had symptoms at the time of testing. Thirty-seven (3.4%) donations tested positive for SARS-CoV-2 RNA, 11 (30%) were confirmed by another molecular assay, and 7 (19%) by sequencing, confirming low viral level. Most RNAemic blood donors donated in southern regions and in Paris. There was no difference in demographic data or duration parameter between RNAemic and non-RNAemic donors. Duration parameter was determined as the time elapsed between donation and: i) the onset of symptoms; ii) a positive NP RT-PCR; and iii) PDI. Cell culture experiments did not show any infectivity related to RNAemic plasmas.
    Discussion: SARS-CoV-2 RNA can be detected in a small fraction of blood donors with PDI, reporting very low levels of RNA. The corresponding plasma is probably not infectious. These findings highlight the value of haemovigilance and PDI to guide blood safety strategies.
    MeSH term(s) Blood Donors ; Blood Safety ; COVID-19/epidemiology ; Humans ; RNA, Viral ; SARS-CoV-2
    Chemical Substances RNA, Viral
    Language English
    Publishing date 2022-01-21
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2135732-8
    ISSN 2385-2070 ; 0041-1787 ; 1723-2007
    ISSN (online) 2385-2070
    ISSN 0041-1787 ; 1723-2007
    DOI 10.2450/2022.0266-21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Human immunodeficiency virus, hepatitis C virus and hepatitis B virus incidence in blood donors from 2000 to 2020 in France: Trends and lessons from haemovigilance surveillance.

    Laperche, Syria / Sauvage, Claire / Gallian, Pierre / Jbilou, Saadia / Pouchol, Elodie / Py, Jean Yves / Chabli, Lila / Richard, Pascale / Morel, Pascal / Lot, Florence / Tiberghien, Pierre

    Vox sanguinis

    2023  Volume 118, Issue 10, Page(s) 843–853

    Abstract: Background and objectives: Data from 21 years (2000-2020) of haemovigilance were used to assess human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) incidence rates in repeat blood donors and the occurrence of ... ...

    Abstract Background and objectives: Data from 21 years (2000-2020) of haemovigilance were used to assess human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) incidence rates in repeat blood donors and the occurrence of transfusion-transmitted (TT) viral infections.
    Materials and methods: Blood donors who converted for HIV, HCV or HBV markers within serial three-year analysis periods were included. Epidemiological and virological data were retrieved from the national epidemiological donor database and were supplemented with information on blood components and the infection status of recipients of the previous negative donation (D.N-1) of donors who seroconverted.
    Results: Incidence rates declined from 1.27 to 0.35/100,000 person-years for HIV, from 0.59 to 0.19 for HCV and from 1.66 to 0.18 for HBV. Risk factors and lookback for 232 HIV, 90 HCV and 74 HBV seroconversions were investigated. The main risk factor identified at post-donation interview was having sex with men (47.8% of males) for HIV and a sexual risk for HCV (30.6%) and HBV (37.1%). The viral loads and sequences were retrospectively tested in 191 HIV, 74 HCV and 62 HBV D.N-1 archived samples. Six (five HBV and one HIV-1) were positive all low viral loads. Two recipients were infected by red blood cells from two HBV seroconverting donors before the introduction of HBV-nucleic acid testing.
    Conclusion: HIV, HCV and HBV incidence rates in blood donors declined over the two past decades in France. There is a very small risk of a blood component that tests negative entering the blood supply resulting in TT infections, especially after introduction of molecular assays in donor screening.
    Language English
    Publishing date 2023-09-11
    Publishing country England
    Document type Journal Article
    ZDB-ID 80313-3
    ISSN 1423-0410 ; 0042-9007
    ISSN (online) 1423-0410
    ISSN 0042-9007
    DOI 10.1111/vox.13514
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Implementation of amotosalen plus ultraviolet A-mediated pathogen reduction for all platelet concentrates in France: Impact on the risk of transfusion-transmitted infections.

    Richard, Pascale / Pouchol, Elodie / Sandid, Imad / Aoustin, Laurent / Lefort, Caroline / Chartois, Anne-Gaële / Baima, Alexis / Malard, Lucile / Bacquet, Caroline / Ferrera-Tourenc, Virginie / Gallian, Pierre / Laperche, Syria / Bliem, Cathy / Morel, Pascal / Tiberghien, Pierre

    Vox sanguinis

    2023  Volume 119, Issue 3, Page(s) 212–218

    Abstract: Background and objectives: Pathogen reduction (PR) technology may reduce the risk of transfusion-transmitted infections (TTIs), notably transfusion-transmitted bacterial infection (TTBI) associated with platelet concentrates (PCs). PR (amotosalen/UVA ... ...

    Abstract Background and objectives: Pathogen reduction (PR) technology may reduce the risk of transfusion-transmitted infections (TTIs), notably transfusion-transmitted bacterial infection (TTBI) associated with platelet concentrates (PCs). PR (amotosalen/UVA treatment) was implemented for all PCs transfused in France in November 2017. No bacterial detection was in place beforehand. The study aimed to assess the impact of PR PC on TTI and TTBI near-miss occurrences.
    Materials and methods: TTI and TTBI near-miss occurrences were compared before and after 100% PR implementation. The study period ran from 2013 to 2022. Over 300,000 PCs were transfused yearly.
    Results: No PC-related transmission of human immunodeficiency virus, hepatitis C virus, hepatitis B virus and human T-cell lymphotropic virus was reported throughout the study period. PC-mediated hepatitis E virus and hepatitis A virus infections occurred irrespective of PR implementation. Mean PC-mediated TTBI occurrence before PR-PC implementation was 3/year (SD: 1; n = 15; 1/92,687 PC between 2013 and 2016) with a fatal outcome in two patients. Since PR implementation, one TTBI has been reported (day 4 PC, Bacillus cereus) (1/1,645,295 PC between 2018 and 2022; p < 0.001). Two PR PC quarantined because of a negative swirling test harboured bacteria: a day 6 PC in 2021 (B. cereus and Staphylococcus epidermidis) and a day 7 PC in 2022 (Staphylococcus aureus). Five similar occurrences with untreated PC were reported between 2013 and 2020.
    Conclusion: Transfusion of 100% PR PC resulted in a steep reduction in TTBI occurrence. TTBI may, however, still occur. Pathogen-reduced PC-related TTI involving non-enveloped viruses occurs as well.
    MeSH term(s) Humans ; Blood Platelets/microbiology ; Furocoumarins ; Transfusion Reaction/epidemiology ; Blood Transfusion ; Bacteria ; Platelet Transfusion/adverse effects ; Ultraviolet Rays
    Chemical Substances amotosalen (K1LDZ0VBC0) ; Furocoumarins
    Language English
    Publishing date 2023-12-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 80313-3
    ISSN 1423-0410 ; 0042-9007
    ISSN (online) 1423-0410
    ISSN 0042-9007
    DOI 10.1111/vox.13574
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?

    Tiberghien, Pierre / de Lamballerie, Xavier / Morel, Pascal / Gallian, Pierre / Lacombe, Karine / Yazdanpanah, Yazdan

    Vox sanguinis

    2020  Volume 115, Issue 6, Page(s) 488–494

    Abstract: Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that ... ...

    Abstract Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality.
    MeSH term(s) Blood Safety/methods ; Blood Safety/standards ; Blood Specimen Collection/methods ; Blood Specimen Collection/standards ; Coronavirus Infections/blood ; Coronavirus Infections/immunology ; Coronavirus Infections/therapy ; Humans ; Immunization, Passive/methods ; Immunization, Passive/standards ; Pandemics ; Pneumonia, Viral/blood ; Pneumonia, Viral/immunology ; Pneumonia, Viral/therapy
    Keywords covid19
    Language English
    Publishing date 2020-05-03
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 80313-3
    ISSN 1423-0410 ; 0042-9007
    ISSN (online) 1423-0410
    ISSN 0042-9007
    DOI 10.1111/vox.12926
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Risk of a blood donation contaminated with hepatitis E virus entering the blood supply before the implementation of universal RNA screening in France.

    Pillonel, Josiane / Maugard, Claude / Sommen, Cécile / Figoni, Julie / Pierre, Chloé / LeCam, Sophie / Richard, Pascale / Morel, Pascal / Gallian, Pierre / Laperche, Syria

    Vox sanguinis

    2022  

    Abstract: Background and objectives: The risk of a blood donation contaminated with hepatitis E virus (HEV) entering the blood supply before introducing universal HEV-RNA screening in France was estimated to assess the benefit of such a measure.: Materials and ... ...

    Abstract Background and objectives: The risk of a blood donation contaminated with hepatitis E virus (HEV) entering the blood supply before introducing universal HEV-RNA screening in France was estimated to assess the benefit of such a measure.
    Materials and methods: The results of selective HEV nucleic acid testing (HEV-NAT) performed in mini pool of six plasma donations between 2018 and 2020 were extrapolated to the whole blood donor (BD) population after adjustment on three variables: regional establishment, sex and age group.
    Results: Among the 246,285 plasma donations collected from 172,635 BDs tested for HEV-RNA, 248 (10.1/10,000) were positive. The extrapolation to all BDs led to an estimated rate of 5.9/10,000 donations (95% confidence interval [CI]: 4.5-7.4) which would be positive to HEV-RNA and a prevalence of 9.9/10,000 BDs (95% CI: 7.5-12.3). This prevalence was 4.4 times higher in males than females (16.8/10,000 vs. 3.8/10,000, p < 10
    Conclusion: The risk of an HEV-RNA-positive donation entering the blood supply was estimated at 1 in 1682 donations. This risk does not translate directly to the risk of HEV transfusion transmission, which mainly depends on the total number of viral particles in the transfused blood component and the sensitivity of NAT.
    Language English
    Publishing date 2022-11-17
    Publishing country England
    Document type Journal Article
    ZDB-ID 80313-3
    ISSN 1423-0410 ; 0042-9007
    ISSN (online) 1423-0410
    ISSN 0042-9007
    DOI 10.1111/vox.13375
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top